Dexmedetomidine for Attenuation of Pressor Response

Phase 4

Completed

• Conditions: Pressor Response
• Interventions: Drug: PRECEDEX INJ★ 2ML

• Registration Number: NCT06592027
• Lead Sponsor: Theodor Bilharz Research Institute

Brief Summary

Direct laryngoscopy and tracheal intubation are usually associated by hemodynamic changes due to increased sympathoadrenal activity which could precipitate serious negative effects in compromised patients . The pressor response could be blunted by dexmedetomidine which is a selective alpha 2 agonist which might provide hemodynamic stability during tracheal intubation.

Detailed Description

Various drugs include local anesthetics, beta-blockers, calcium channel blockers, and narcotic analgesics have been tried to blunt the laryngoscopy and intubation response, with varied success. Dexmedetomidine is a potent and highly selective alpha-2 receptor agonist with sympatholytic, sedative, amnestic, and analgesic properties. Its various effects have led to its increasing use for reducing anesthetic and analgesic requirements in the perioperative period. It inhibits sympathetic activity thus terminating the pain signals and thereby blunts the pressor response associated with laryngoscopy and endotracheal intubation. Electrical cardiometry is recently introduced for assessment of many cardiovascular variables and continuously applicable method of cardiac output (CO), stroke volume (SV), and other hemodynamic parameters monitoring. Its use is growing because it is non-invasive, shows reliability in CO measurements and can be used as a continuous bedside monitor Although different doses of dexmedetomidine (0.5- 2.0 μg/kg) have been used in various studies which suggested its efficacy in blunting the hemodynamic pressor response , However, no studies to the best of our knowledge had incorporated CO monitoring for detection of minimal hemodynamic changes during laryngoscopy and endotracheal intubation which can be best achieved by using Cardiometry monitor.

In this study, we will compare two doses of dexmedetomidine for prophylaxis against pressor response of ETI using cardiometry.

Study Timeline

• Study Start: 2024-02-01
• Primary Completion: 2024-05-01
• Study Completion: 2024-05-30
• Status Verified: 2024-09
• Study First Submitted: 2024-09-08
• Study First Submitted QC: 2024-09-08
• Last Update Submitted: 2024-09-08
• Study First Posted: 2024-09-11
• Last Update Posted: 2024-09-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1 - ASA physical status 1-2. 2. Age 18- 60 years old of both sexes. 3. Patients undergoing elective surgery under general anesthesia and tracheal intubation.

Read More

Exclusion Criteria

1. Age < 18 years and ≥ 60 years
2. Pregnancy
3. Emergency surgery or full stomach
4. Renal or Hepatic patients
5. Patients with suspected difficult airway {e.g., high neck circumference, high body mass index (above 30 kg/m2), airway masses, mouth scars, neck scars, limited neck extension or history of snoring.
6. Total duration of laryngoscopy will be noted and in cases where duration exceeded 15 sec the case will be excluded from the study.
7. Any patient on regular intake of beta blockers or calcium channel blockers
8. Patients with any known hypersensitivity or contraindication to dexmedetomidine,
9. Patients with significant neurological, psychiatric, or neuromuscular disorders.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group B	PRECEDEX INJ★ 2ML	this group will receive single dose of dexmedetomidine 1 mcg /kg in 50 ml normal saline over 10 min IV infusion
Group A	PRECEDEX INJ★ 2ML	this group will receive single dose of dexmedetomidine 0.5 mcg /kg in 50 ml normal saline over 10 min IV infusion

Primary Outcome Measures

Name	Time	Method
Heart rate measurment	after 1 minute of successful tracheal intubation	single measurement after intubation

Secondary Outcome Measures

Name	Time	Method
cardiac output	from the start of induction of anesthesia till 5 minutes after successful tracheal intubation	serial measurements every 1 minute

Trial Locations

Locations (1)

Theodor Bilharz Research institute; 🇪🇬 Giza, Egypt